What We're Reading: Page 161
Industry reads hand-picked by our editors
Apr 26, 2021
-
Bloomberg
The First Billion Doses
-
FiercePharma
ADC Therapeutics scores FDA approval for anti-CD19 blood cancer med Zynlonta
-
The Washington Post
Vaccine maker Emergent's CEO sold $10 million in stock before company ruined Johnson & Johnson doses
-
Evaluate Vantage
Bristol's Tyk2 ticks the boxes
Apr 23, 2021
-
The New York Times
With Few New Clotting Cases, Johnson & Johnson Pause Could Be Lifted Soon
-
Life Sci VC
Five Macro Risks To Biotech Coming Out of Washington | LifeSciVC
-
The Financial Times
Scientists split over advice on giving AstraZeneca jab to UK under-40s
Apr 22, 2021
-
The Wall Street Journal
Biotech Stocks Fall Out of Favor After Disappointing Trial Results, Big Rally
-
Endpoints News
As fears mount over J&J and AstraZeneca, Novavax enters a shaky spotlight
-
Bloomberg
Pfizer to Place 100 Young Minorities in New Fellowship Program
-
MIT Technology Review
New preconception testing could predict your child's risk to common diseases
Apr 21, 2021
Apr 20, 2021
-
Fortune
This biotech startup thinks it can delay menopause by 15 years. That would transform women’s lives
-
Chemical & Engineering News
Making stem cell transplants safer
-
STAT
Genetically targeted drug from Syndax Pharma shows remissions in leukemia patients
-
The New York Times
Emergent BioSolutions halts operations at its Baltimore plant, where J.&J. doses were ruined, at the F.D.A.’s request.
Apr 19, 2021
-
ProPublica
A Tiny Number of People Will Be Hospitalized Despite Being Vaccinated. We Have to Learn Why.
-
The Wall Street Journal
Drugmakers Go on Trial Over Opioid Epidemic
-
Time
Inside the Facilities Making the World's Most Prevalent COVID-19 Vaccine
-
The New York Times
The Covid-19 Plasma Boom Is Over. What Did We Learn From It?
Apr 16, 2021
-
The Wall Street Journal
J&J Privately Asked Rival Covid-19 Vaccine Makers to Probe Clotting Risks
-
NPR
Scientists Create Early Embryos That Are Part Human, Part Monkey
-
Bloomberg
Unused Vaccines Are Piling Up Across U.S. as Some Regions Resist
-
Endpoints News
Osman Kibar lays down his hand at Samumed, stepping away from CEO role as his once-heralded anti-aging biotech rebrands
Previous
